NxStage Medical, Inc. Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
Published: Sep 10, 2012
LAWRENCE, Mass., Sept. 10, 2012 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced Todd M. Snell has joined the Company as Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs.
"NxStage has a strong culture of compliance and tradition of high quality and excellence in delivering renal products to patients and customers worldwide," said Jeffrey H. Burbank, President and CEO of NxStage Medical. "Todd will play a significant role in our future growth and success as we seek to advance multiple products through clinical and regulatory processes."
"NxStage's ongoing innovation in renal care makes them a leader in the industry," said Todd Snell. "I am excited to join the NxStage team and look forward to helping advance NxStage's ongoing commitment to quality and excellence."
Snell brings to NxStage more than 20 years of quality and operational leadership experience with over 13 years in the healthcare industry, overseeing quality assurance and compliance for vascular care products, rare disease treatments and other therapeutic areas. Most recently, Snell served as the Vice President of Quality Assurance, Regulatory Affairs for Vascular Therapies at Covidien. Other previous positions include Vice President of Quality and Regulatory Compliance at Genzyme Corporation and Quality Systems Leader at GE Medical Systems. Prior to his work in healthcare, Snell served as a Captain in the United States Army.
Mr. Snell received his BS in Systems Engineering from the United States Military Academy (West Point, NY) and his MBA in Operations Management from University of Colorado (Colorado Springs).
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ES RD, and acute kidney failure. NxStage is leading the development of the home dialysis market in the US with the only portable dialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
VP, Investor Relations
SOURCE NxStage Medical, Inc.